MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412816 | Name: Indantadol (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Indantadol (free base) is an NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain.

Chemical Structure

Indantadol (free base)
Indantadol (free base)
CAS#202844-10-8 (free base)

Theoretical Analysis

MedKoo Cat#: 412816

Name: Indantadol (free base)

CAS#: 202844-10-8 (free base)

Chemical Formula: C11H14N2O

Exact Mass: 190.1106

Molecular Weight: 190.25

Elemental Analysis: C, 69.45; H, 7.42; N, 14.73; O, 8.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
202914-18-9 (HCl) 202844-10-8 (free base)
Synonym
Indantadol; CHF3381; CHF-3381; CHF 3381
IUPAC/Chemical Name
2-((2,3-dihydro-1H-inden-2-yl)amino)acetamide
InChi Key
MNLULKBKWKTZPE-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H14N2O/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10/h1-4,10,13H,5-7H2,(H2,12,14)
SMILES Code
NC(CNC1Cc2c(C1)cccc2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 190.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mattia C, Coluzzi F. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44. PMID: 17786847. 2: Vilums M, Heuberger J, Heitman LH, IJzerman AP. Indanes--Properties, Preparation, and Presence in Ligands for G Protein Coupled Receptors. Med Res Rev. 2015 Nov;35(6):1097-126. doi: 10.1002/med.21352. Epub 2015 May 27. PMID: 26018667. 3: CHF 3381. Drugs R D. 2004;5(1):28-30. doi: 10.2165/00126839-200405010-00005. PMID: 14725488. 4: Barbieri M, Bregola G, Buzzi A, Marino S, Zucchini S, Stables JP, Bergamaschi M, Pietra C, Villetti G, Simonato M. Mechanisms of action of CHF3381 in the forebrain. Br J Pharmacol. 2003 Aug;139(7):1333-41. doi: 10.1038/sj.bjp.0705381. PMID: 12890713; PMCID: PMC1573965. 5: Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, Rondelli I, Chamiot-Clerc P, Simonato M, Barbieri M. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Aug;306(2):804-14. doi: 10.1124/jpet.103.050039. Epub 2003 May 15. PMID: 12750440. 6: Bassani F, Bergamaschi M, Tonino Bolzoni P, Villetti G. CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. Eur J Pharmacol. 2005 Sep 20;519(3):231-6. doi: 10.1016/j.ejphar.2005.07.004. PMID: 16125167. 7: Csajka C, Imbimbo BP, Piccinno A, Dostert P, Verotta D. Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. J Pharmacol Exp Ther. 2005 May;313(2):647-57. doi: 10.1124/jpet.104.080457. Epub 2005 Jan 25. PMID: 15671203. 8: Astruc B, Tarral A, Dostert P, Mariotti F, Fabbri L, Imbimbo BP. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. Br J Clin Pharmacol. 2005 Apr;59(4):405-14. doi: 10.1111/j.1365-2125.2005.02338.x. PMID: 15801935; PMCID: PMC1884805. 9: Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB. CHF3381, a N-methyl- D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model. J Pain. 2006 Aug;7(8):565-74. doi: 10.1016/j.jpain.2006.02.004. PMID: 16885013. 10: Villetti G, Bregola G, Bassani F, Bergamaschi M, Rondelli I, Pietra C, Simonato M. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacology. 2001 Jun;40(7):866-78. doi: 10.1016/s0028-3908(01)00026-0. PMID: 11378157.